EPO and chronic kidney disease: In patients with end-stage renal disease, uremia leads to a reduced number and function of lymphoid cells, premature “aging” of hematopoietic stem cell composition, altered renal metabolic activities with depleted production (renin, erythropoietin, and vitamin D), and increased susceptibility to infection [108,109].